









Markets
/
Stocks
/
nasdaq-biaf
/

bioAffinity Technologies Inc

BIAF

3.659USD

-1.081-22.80%

Market hours （ET）Quotes delayed by 15 min

9.98MMarket Cap

LossP/E TTM



bioAffinity Technologies Inc

3.659

-1.081-22.80%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of bioAffinity Technologies Inc

Currency: USD Updated: 2026-03-27

Key Insights

bioAffinity Technologies Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 139 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is low.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 6.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

bioAffinity Technologies Inc's Score

Industry at a Glance

Industry Ranking

139 / 208

Overall Ranking

386 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

bioAffinity Technologies Inc Highlights

StrengthsRisks

bioAffinity Technologies, Inc. is a biotechnology company focused on the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 143.32% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 6.16M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 6.16M.

Overvalued

The company’s latest PE is -0.46, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.80.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

6.000

Target Price

+2190.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of bioAffinity Technologies Inc is 6.18, ranking 165 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.59M, representing a year-over-year decrease of 27.85%, while its net profit experienced a year-over-year decrease of 5.75%.

Score

Industry at a Glance

Previous score

6.18

Change



Financials

9.73

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.33

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

bioAffinity Technologies Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of bioAffinity Technologies Inc is 6.39, ranking 163 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.46, which is -92.18% below the recent high of -0.04 and -1543.90% above the recent low of -7.59.

Score

Industry at a Glance

Previous score

6.39

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 139/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

No earnings forecast score is currently available for bioAffinity Technologies Inc. The Healthcare Equipment & Supplies industry's average is 7.78. The average price target is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

6.000

Target Price

+2190.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

bioAffinity Technologies Inc

BIAF

Medtronic PLC

MDT

Stryker Corp

SYK

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

Abbott Laboratories

ABT

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of bioAffinity Technologies Inc is 9.35, ranking 2 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 5.94 and the support level at 1.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.68

Change

-0.33

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.506

Buy

RSI(14)

64.760

Neutral

STOCH(KDJ)(9,3,3)

66.715

Neutral

ATR(14)

0.977

High Vlolatility

CCI(14)

94.289

Neutral

Williams %R

31.834

Buy

TRIX(12,20)

7.569

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

4.280

Sell

MA10

3.418

Buy

MA20

2.293

Buy

MA50

1.594

Buy

MA100

1.561

Buy

MA200

4.172

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of bioAffinity Technologies Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 0.39%, representing a quarter-over-quarter decrease of 35.45%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Crumly (Richard K)

60.25K

Bigger Capital Funds, LP

58.68K

District 2 Capital LP

58.68K

Girgenti (Steven)

36.30K

-0.01%

The Joyce Living Trust

20.25K

+4.20%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of bioAffinity Technologies Inc is 1.49, ranking 188 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is -1.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.